The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neuropathic Pain Management Market Research Report 2024
Synopsis
Neuropathic pain management refers to a way to relieve and treat neuropathic pain through various drugs or treatments.
The global Neuropathic Pain Management market was valued at US$ 8527 million in 2023 and is anticipated to reach US$ 10690 million by 2030, witnessing a CAGR of 3.2% during the forecast period 2024-2030.
North American market for Neuropathic Pain Management is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Neuropathic Pain Management is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Neuropathic Pain Management in Retail Pharmacy is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Neuropathic Pain Management include Pfizer, Johnson & Johnson Services, Sanofi, GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, Biogen Idec, Baxter Healthcare Corporation and Depomed, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neuropathic Pain Management, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuropathic Pain Management.
Report Scope
The Neuropathic Pain Management market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuropathic Pain Management market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuropathic Pain Management companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Johnson & Johnson Services
Sanofi
GlaxoSmithKline
Eli Lilly and Company
Bristol-Myers Squibb
Biogen Idec
Baxter Healthcare Corporation
Depomed
Segment by Type
Tricyclic Antidepressant
Anticonvulsant
Opioid
Steroid Drug
Local Anesthesia
Other
Segment by Application
Retail Pharmacy
Hospital Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuropathic Pain Management companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Neuropathic pain management refers to a way to relieve and treat neuropathic pain through various drugs or treatments.
The global Neuropathic Pain Management market was valued at US$ 8527 million in 2023 and is anticipated to reach US$ 10690 million by 2030, witnessing a CAGR of 3.2% during the forecast period 2024-2030.
North American market for Neuropathic Pain Management is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Neuropathic Pain Management is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Neuropathic Pain Management in Retail Pharmacy is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Neuropathic Pain Management include Pfizer, Johnson & Johnson Services, Sanofi, GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, Biogen Idec, Baxter Healthcare Corporation and Depomed, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neuropathic Pain Management, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuropathic Pain Management.
Report Scope
The Neuropathic Pain Management market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuropathic Pain Management market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuropathic Pain Management companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Johnson & Johnson Services
Sanofi
GlaxoSmithKline
Eli Lilly and Company
Bristol-Myers Squibb
Biogen Idec
Baxter Healthcare Corporation
Depomed
Segment by Type
Tricyclic Antidepressant
Anticonvulsant
Opioid
Steroid Drug
Local Anesthesia
Other
Segment by Application
Retail Pharmacy
Hospital Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuropathic Pain Management companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuropathic Pain Management Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Tricyclic Antidepressant
1.2.3 Anticonvulsant
1.2.4 Opioid
1.2.5 Steroid Drug
1.2.6 Local Anesthesia
1.2.7 Other
1.3 Market by Application
1.3.1 Global Neuropathic Pain Management Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Retail Pharmacy
1.3.3 Hospital Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuropathic Pain Management Market Perspective (2019-2030)
2.2 Neuropathic Pain Management Growth Trends by Region
2.2.1 Global Neuropathic Pain Management Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neuropathic Pain Management Historic Market Size by Region (2019-2024)
2.2.3 Neuropathic Pain Management Forecasted Market Size by Region (2025-2030)
2.3 Neuropathic Pain Management Market Dynamics
2.3.1 Neuropathic Pain Management Industry Trends
2.3.2 Neuropathic Pain Management Market Drivers
2.3.3 Neuropathic Pain Management Market Challenges
2.3.4 Neuropathic Pain Management Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuropathic Pain Management Players by Revenue
3.1.1 Global Top Neuropathic Pain Management Players by Revenue (2019-2024)
3.1.2 Global Neuropathic Pain Management Revenue Market Share by Players (2019-2024)
3.2 Global Neuropathic Pain Management Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neuropathic Pain Management Revenue
3.4 Global Neuropathic Pain Management Market Concentration Ratio
3.4.1 Global Neuropathic Pain Management Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuropathic Pain Management Revenue in 2023
3.5 Neuropathic Pain Management Key Players Head office and Area Served
3.6 Key Players Neuropathic Pain Management Product Solution and Service
3.7 Date of Enter into Neuropathic Pain Management Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuropathic Pain Management Breakdown Data by Type
4.1 Global Neuropathic Pain Management Historic Market Size by Type (2019-2024)
4.2 Global Neuropathic Pain Management Forecasted Market Size by Type (2025-2030)
5 Neuropathic Pain Management Breakdown Data by Application
5.1 Global Neuropathic Pain Management Historic Market Size by Application (2019-2024)
5.2 Global Neuropathic Pain Management Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neuropathic Pain Management Market Size (2019-2030)
6.2 North America Neuropathic Pain Management Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neuropathic Pain Management Market Size by Country (2019-2024)
6.4 North America Neuropathic Pain Management Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neuropathic Pain Management Market Size (2019-2030)
7.2 Europe Neuropathic Pain Management Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neuropathic Pain Management Market Size by Country (2019-2024)
7.4 Europe Neuropathic Pain Management Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neuropathic Pain Management Market Size (2019-2030)
8.2 Asia-Pacific Neuropathic Pain Management Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neuropathic Pain Management Market Size by Region (2019-2024)
8.4 Asia-Pacific Neuropathic Pain Management Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neuropathic Pain Management Market Size (2019-2030)
9.2 Latin America Neuropathic Pain Management Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neuropathic Pain Management Market Size by Country (2019-2024)
9.4 Latin America Neuropathic Pain Management Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuropathic Pain Management Market Size (2019-2030)
10.2 Middle East & Africa Neuropathic Pain Management Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neuropathic Pain Management Market Size by Country (2019-2024)
10.4 Middle East & Africa Neuropathic Pain Management Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neuropathic Pain Management Introduction
11.1.4 Pfizer Revenue in Neuropathic Pain Management Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Johnson & Johnson Services
11.2.1 Johnson & Johnson Services Company Detail
11.2.2 Johnson & Johnson Services Business Overview
11.2.3 Johnson & Johnson Services Neuropathic Pain Management Introduction
11.2.4 Johnson & Johnson Services Revenue in Neuropathic Pain Management Business (2019-2024)
11.2.5 Johnson & Johnson Services Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Neuropathic Pain Management Introduction
11.3.4 Sanofi Revenue in Neuropathic Pain Management Business (2019-2024)
11.3.5 Sanofi Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Detail
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Neuropathic Pain Management Introduction
11.4.4 GlaxoSmithKline Revenue in Neuropathic Pain Management Business (2019-2024)
11.4.5 GlaxoSmithKline Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Detail
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Neuropathic Pain Management Introduction
11.5.4 Eli Lilly and Company Revenue in Neuropathic Pain Management Business (2019-2024)
11.5.5 Eli Lilly and Company Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Detail
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Neuropathic Pain Management Introduction
11.6.4 Bristol-Myers Squibb Revenue in Neuropathic Pain Management Business (2019-2024)
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Biogen Idec
11.7.1 Biogen Idec Company Detail
11.7.2 Biogen Idec Business Overview
11.7.3 Biogen Idec Neuropathic Pain Management Introduction
11.7.4 Biogen Idec Revenue in Neuropathic Pain Management Business (2019-2024)
11.7.5 Biogen Idec Recent Development
11.8 Baxter Healthcare Corporation
11.8.1 Baxter Healthcare Corporation Company Detail
11.8.2 Baxter Healthcare Corporation Business Overview
11.8.3 Baxter Healthcare Corporation Neuropathic Pain Management Introduction
11.8.4 Baxter Healthcare Corporation Revenue in Neuropathic Pain Management Business (2019-2024)
11.8.5 Baxter Healthcare Corporation Recent Development
11.9 Depomed
11.9.1 Depomed Company Detail
11.9.2 Depomed Business Overview
11.9.3 Depomed Neuropathic Pain Management Introduction
11.9.4 Depomed Revenue in Neuropathic Pain Management Business (2019-2024)
11.9.5 Depomed Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
